|
Palo Alto, CA, July 25, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that its second quarter 2003 conference call and
webcast will be held on Wednesday, July 30, 2003 at 4:30 p.m. Eastern
time (1:30 p.m. Pacific time). The call will follow the release
of Telik’s second quarter 2003 financial results earlier
that day. Michael M. Wick M.D., Ph.D., Telik’s chairman and
chief executive officer, and Cynthia M. Butitta, the company’s
chief operating officer and chief financial officer, will present
the company’s financial results and discuss progress in Telik’s
clinical development programs.
Participants may access the live webcast via Telik’s website
at www.telik.com or by telephone at (612) 288 0318. A replay of
the webcast will be available on the Telik website from approximately
8:30 p.m. Eastern time on July 30 through August 6, 2003.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™ (TLK286), a tumor activated small molecule drug that
is in a Phase 3 registration clinical trial in ovarian cancer and
in clinical trials in non-small cell lung, colorectal and breast
cancer. TLK199 is in a Phase 1-2a trial in myelodysplastic syndrome,
a form of pre-leukemia. Telik’s product candidates were discovered
using its proprietary drug discovery technology, TRAP, which enables
the rapid and efficient discovery of small molecule drug candidates.
Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
